FromSoftware's expansions are known for their difficulty, and we can easily prove it with this ranked list of the ten hardest ...

Pharmaceuticals announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia, CAH, study of ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Mineralys Therapeutics (MLYS) announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to ...

Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical ...

As the months ticked by, Garvey said in March of this year that “we are not hearing anything new from Amazon about Phase 2.” “The expectation still is that they will move forward with Phase ...

Babylon Phase-2 testnet launches on January 8, 2025, featuring Bitcoin PoS and staking upgrades. Faucets provide test Signet BTC and tBABY tokens for Phase-2 participation starting after launch. The ...